Additional Reassuring Data for SARS-CoV-2 Vaccination in Immune-Mediated Inflammatory Diseases, but With a Catch.

Abstract

Vaccination remains the most important intervention to attenuate the risk and severity of infectious diseases in those immunosuppressed for the treatment of rheumatic conditions and is indeed true for coronavirus disease 2019 (COVID-19). Substantial reductions in the hazard ratios (HRs) of breakthrough infections were observed in those with immune-mediated inflammatory diseases (IMIDs) vaccinated with the initial series (HR 0.143) and after the third dose (HR 0.017) of BNT162b2 compared to unvaccinated patients.¹.